Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1471-2377

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease ; volume:20 ; number:1 ; day:9 ; month:1 ; year:2020 ; pages:1-12 ; date:12.2020
BMC neurology ; 20, Heft 1 (9.1.2020), 1-12, 12.2020

Creator: Wattmo, Carina
Blennow, Kaj
Hansson, Oskar

Contributor: SpringerLink (Online service)

DOI: 10.1186/s12883-019-1591-0

URN: urn:nbn:de:101:1-2020052417063486796538

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 11:02 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Wattmo, Carina
Blennow, Kaj
Hansson, Oskar
SpringerLink (Online service)

Other Objects (12)

Tau-related grey matter network breakdown across the Alzheimer’s disease continuum

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease

Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer’s Disease

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias

Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease

Fluid biomarkers in Alzheimer’s disease – current concepts

Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers

18 F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease

Greater tau load and reduced cortical thickness in APOE ε4-negative Alzheimer’s disease: a cohort study

Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease

Higher levels of myelin are associated with higher resistance against tau pathology in Alzheimer’s disease

Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer’s disease pathology

Tau-related grey matter network breakdown across the Alzheimer’s disease continuum

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease

Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer’s Disease

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias

Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease

Fluid biomarkers in Alzheimer’s disease – current concepts

Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers

18 F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease

Greater tau load and reduced cortical thickness in APOE ε4-negative Alzheimer’s disease: a cohort study

Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease

Higher levels of myelin are associated with higher resistance against tau pathology in Alzheimer’s disease

Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer’s disease pathology

Tau-related grey matter network breakdown across the Alzheimer’s disease continuum

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease

Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer’s Disease

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias

Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease

Fluid biomarkers in Alzheimer’s disease – current concepts

Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers

18 F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease

Greater tau load and reduced cortical thickness in APOE ε4-negative Alzheimer’s disease: a cohort study

Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease

Higher levels of myelin are associated with higher resistance against tau pathology in Alzheimer’s disease

Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer’s disease pathology

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Tau-related grey matter network breakdown across the Alzheimer’s disease continuum

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease

Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer’s Disease

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias

Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease

Fluid biomarkers in Alzheimer’s disease – current concepts

Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers

18 F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease

Greater tau load and reduced cortical thickness in APOE ε4-negative Alzheimer’s disease: a cohort study

Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease

Higher levels of myelin are associated with higher resistance against tau pathology in Alzheimer’s disease

Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer’s disease pathology

Tau-related grey matter network breakdown across the Alzheimer’s disease continuum

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease

Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer’s Disease

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias

Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease

Fluid biomarkers in Alzheimer’s disease – current concepts

Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers

18 F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease

Greater tau load and reduced cortical thickness in APOE ε4-negative Alzheimer’s disease: a cohort study

Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease

Higher levels of myelin are associated with higher resistance against tau pathology in Alzheimer’s disease

Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer’s disease pathology

Tau-related grey matter network breakdown across the Alzheimer’s disease continuum

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease

Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer’s Disease

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias

Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease

Fluid biomarkers in Alzheimer’s disease – current concepts

Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers

18 F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease

Greater tau load and reduced cortical thickness in APOE ε4-negative Alzheimer’s disease: a cohort study

Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease

Higher levels of myelin are associated with higher resistance against tau pathology in Alzheimer’s disease

Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer’s disease pathology

Related objects

Reset password